A case study applying a novel approach to estimate the social impact of a medical innovation - the use of secukinumab for psoriatic arthritis in Germany

References

• Gordon KB, Ruderman EM, eds. Psoriasis and psoriatic arthritis: an integrated approach. Berlin, Heidelberg: Springer-Verlag Berlin Heidelberg; 2005.
   Google Scholar
• Saraux A, Guillemin F, Guggenbuhl P, et al. Prevalence of spondyloarthropathies in France: 2001. Ann Rheum Dis. 2005;64:1431–1435.
   PubMed Web of Science ®Google Scholar
• Salaffi F, de Angelis R, Grassi W. Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clin Exp Rheumatol. 2005;23:819–828.
   PubMed Web of Science ®Google Scholar
• HRI & Elsevier HA. Analyse der Versorgung von Versicherten mit Psoriasis - eine retrospektive Beobachtungsstudie auf Basis von GKV-Routinedaten (Ergebnistabellen); 2013.
   Google Scholar
• Rosen CF, Mussani F, Chandran V, et al. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology (Oxford). 2012;51:571–576.
   PubMed Web of Science ®Google Scholar
• Ciocon DH, Horn EJ, Kimball AB. Quality of life and treatment satisfaction among patients with psoriasis and psoriatic arthritis and patients with psoriasis only: results of the 2005 Spring US National Psoriasis Foundation Survey. Am J Clin Dermatol. 2008;9:111–117.
   PubMed Web of Science ®Google Scholar
• Klimeš J, Vocelka M, Šedová L, et al. Medical and productivity costs of rheumatoid arthritis in The Czech Republic: cost-of-illness study based on disease severity. Value Health Reg Issues. 2014;4:75–81.
   PubMedGoogle Scholar
• Thanh NX. Self-reported productivity losses of people with rheumatoid arthritis in Alberta, Canada. TOPHARMEJ. 2013;5:11–14.
   Google Scholar
• Mau W, Beyer W, Ehlebracht-König I, et al. Krankheitslast. Erste Routineberichterstattung zu sozialmedizinischen Folgen entzündlich-rheumatischer Erkrankungen in Deutschland. Z Rheumatol. 2008;67:157–164.
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Ramiro S. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75:499-510.
   Web of Science ®Google Scholar
• Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68:1060–1071.
   PubMed Web of Science ®Google Scholar
• Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80:27–40.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency: Cosentyx: EPAR - Product information; 2018 [cited 2019 Jul 9]. Available from: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf
   Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137–1146.
   PubMed Web of Science ®Google Scholar
• Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab Inhibition of Interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373:1329–1339.
   PubMed Web of Science ®Google Scholar
• Strand V, Mease P, Gossec L, et al. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). Ann Rheum Dis. 2017;76:203–207.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Reimold AM, et al. Secukinumab for long-term treatment of psoriatic arthritis: a two-year followup from a phase III, randomized, double-blind placebo-controlled study. Arthritis Care Res. 2017;69:347–355.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes IB, Mease PJ, et al. Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study. J Rheumatol. 2016;43:1713–1717.
   PubMed Web of Science ®Google Scholar
• Mease P, van der Heijde D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77:890–897.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Ritchlin CT, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology. 2017;56:1993–2003.
   PubMed Web of Science ®Google Scholar
• Goeree R, Chiva-Razavi S, Gunda P, et al. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. J Med Econ. 2018;21:163–173.
   PubMed Web of Science ®Google Scholar
• Buchanan V, Sullivan W, Graham C, et al. Cost effectiveness of secukinumab for the treatment of active psoriatic arthritis in the UK. Pharmacoeconomics. 2018;36:867–878.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey. J Am Acad Dermatol. 2014;70:871–81.e1-30.
   Web of Science ®Google Scholar
• Sondermann W, Ventzke J, Matusiewicz D, et al. Analysis of pharmaceutical care in patients with psoriatic arthritis using statutory health insurance data. J Dtsch Dermatol Ges. 2018;16:285–294.
   Web of Science ®Google Scholar
• Bruce B, Fries JF. The health assessment questionnaire (HAQ). Clin Exp Rheumatol. 2005;23:S14–S18.
   PubMed Web of Science ®Google Scholar
• Ribas SA, Mendes SD, Pires LB, et al. Sensitivity and specificity of assessment instruments of quality of life in rheumatoid arthritis. Rev Bras Reumatol Engl Ed. 2016;56:406–413.
   PubMedGoogle Scholar
• Statistisches Bundesamt. Allgemeine Sterbetafel 2010/12. Wiesbaden: Statistisches Bundesamt; 2015.
   Google Scholar
• Ogdie A, Haynes K, Troxel AB, et al. Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study. Ann Rheum Dis. 2014;73:149–153.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Antoni CE, Gladman DD, et al. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(Suppl 2):ii49–ii54.
   PubMedGoogle Scholar
• Rodgers M, Epstein D, Bojke L, et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2011;15:i-xxi,1–329.
   Web of Science ®Google Scholar
• Novartis. Prediction model strategic plan 17-22. Data on file; 2017.
   Google Scholar
• Adelphi Real World. Understanding the PsA market: Germany PsA deck. Prepared for Novartis. Data on file; 2015.
   Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353–365.
   PubMed Web of Science ®Google Scholar
• Tang K. Estimating productivity costs in health economic evaluations: a review of instruments and psychometric evidence. Pharmacoeconomics. 2015;33:31–48.
   PubMed Web of Science ®Google Scholar
• Krol M, Brouwer WBF, Severens JL, et al. Productivity cost calculations in health economic evaluations: correcting for compensation mechanisms and multiplier effects. Soc Sci Med. 2012;75:1981–1988.
   PubMed Web of Science ®Google Scholar
• Mau W, Thiele K, Lamprecht J. Trends der Erwerbstätigkeit von Rheumakranken: ergebnisse aus Sozialversicherungsdaten und Kerndokumentation der Rheumazentren in Deutschland. Z Rheumatol. 2014;73:11–19.
   PubMedGoogle Scholar
• Institut für Arbeitsmarkt- und Berufsforschung. Arbeitszeitrechnung. Nürnberg; 2015.
   Google Scholar
• Statistisches Bundesamt: Volkswirtschaftliche Gesamtrechnungen: Wichtige Zusammenhänge im Überblick. Statistisches Bundesamt; 2017.
   Google Scholar
• Reid M. Economics of Household Production. New York (NY): J. Wiley & Sons; 1934.
   Google Scholar
• Hofmann S. Einfluss nicht-marktlicher tätigkeiten auf den materiellen wohlstand und die einkommensverteilung in Deutschland. Sozialökonomische Schriften. Frankfurt am Main [Germany], PL Academic Research, 2015, Band 50. : ;, .
   Google Scholar
• Statistisches Bundesamt. Input-Output-Rechnung im Überblick. Wiesbaden: Statistisches Bundesamt; 2010.
   Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health. 2014;17:5–14.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Woolley JM, Bitman B, et al. Minimally important difference of health assessment questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol. 2011;38:2461–2465.
   PubMed Web of Science ®Google Scholar
• Gold MR. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press; 1996.
   Google Scholar
• Conaghan PG, Alten R, Strand V, et al. The relationship between physical functioning and work for people with psoriatic arthritis: results from a large real-world study in 16 countries. Arthritis Rheumatol. 2016;68(suppl 10).
   Google Scholar
• Huscher D, Merkesdal S, Thiele K, et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis. 2006;65:1175–1183.
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Englund M, Neovius M, et al. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study. Ann Rheum Dis. 2013;72:1675–1679.
   PubMedGoogle Scholar
• de Croon EM, Sluiter JK, Nijssen TF, et al. Predictive factors of work disability in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2004;63:1362–1367.
   PubMed Web of Science ®Google Scholar
• Chaparro Del Moral R, Rillo OL, Casalla L, et al. Work productivity in rheumatoid arthritis: relationship with clinical and radiological features. Arthritis. 2012;2012:137635.
   PubMedGoogle Scholar
• Kavanaugh A, Mease PJ, Purcaru O, et al. High economic burden of moderate to severe psoriatic arthritis on paid work and household productivity: baseline results from the rapid-PSA study. Value Health. 2013;16:A566.
   Web of Science ®Google Scholar